Aspirin treatment for women after preeclampsia
Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia
This study is testing if low-dose aspirin can help women who had preeclampsia during pregnancy by improving their heart health and reducing their risk of cardiovascular disease.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT06168461 on ClinicalTrials.gov |
What this trial studies
This study investigates whether low-dose aspirin therapy can effectively treat lasting blood vessel damage in women who have experienced preeclampsia during pregnancy. Given that women with a history of preeclampsia are at a higher risk for cardiovascular disease, the study aims to provide a potential treatment strategy to mitigate this risk. Participants will be randomly assigned to receive either aspirin or a placebo to assess the impact on their cardiovascular health. The findings could inform better clinical management for these women in the future.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older who have had preeclampsia within the past 5 years.
Not a fit: Patients currently using daily aspirin, those with certain medical conditions, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of cardiovascular disease in women who have had preeclampsia.
How similar studies have performed: While this approach is novel in the context of post-preeclampsia treatment, similar studies have shown promise in using aspirin for cardiovascular protection in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * had preeclampsia in the past 5 years, * 18 years or older Exclusion criteria: * current daily aspirin use, * skin diseases, * current tobacco or nicotine use (including vaping), * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * currently pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs, * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Where this trial is running
Iowa City, Iowa
- University of Iowa — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Anna Reid-Stanhewicz, PHD
- Email: anna-stanhewicz@uiowa.edu
- Phone: 319-467-1732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.